JP5976643B2 - 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物 - Google Patents

二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物 Download PDF

Info

Publication number
JP5976643B2
JP5976643B2 JP2013518762A JP2013518762A JP5976643B2 JP 5976643 B2 JP5976643 B2 JP 5976643B2 JP 2013518762 A JP2013518762 A JP 2013518762A JP 2013518762 A JP2013518762 A JP 2013518762A JP 5976643 B2 JP5976643 B2 JP 5976643B2
Authority
JP
Japan
Prior art keywords
strand
catenin
dsrna
rna
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013518762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534425A (ja
JP2013534425A5 (enExample
Inventor
ボブ， デール ブラウン，
ボブ， デール ブラウン，
ヘンリク， ティー ドゥーデック，
ヘンリク， ティー ドゥーデック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of JP2013534425A publication Critical patent/JP2013534425A/ja
Publication of JP2013534425A5 publication Critical patent/JP2013534425A5/ja
Application granted granted Critical
Publication of JP5976643B2 publication Critical patent/JP5976643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013518762A 2010-07-06 2011-07-01 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物 Expired - Fee Related JP5976643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36177610P 2010-07-06 2010-07-06
US61/361,776 2010-07-06
PCT/US2011/042820 WO2012006243A2 (en) 2010-07-06 2011-07-01 Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

Publications (3)

Publication Number Publication Date
JP2013534425A JP2013534425A (ja) 2013-09-05
JP2013534425A5 JP2013534425A5 (enExample) 2014-08-14
JP5976643B2 true JP5976643B2 (ja) 2016-08-24

Family

ID=45441761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518762A Expired - Fee Related JP5976643B2 (ja) 2010-07-06 2011-07-01 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物

Country Status (9)

Country Link
US (5) US8815825B2 (enExample)
EP (4) EP3037538B1 (enExample)
JP (1) JP5976643B2 (enExample)
AU (1) AU2011276365B2 (enExample)
CA (2) CA2804214C (enExample)
DK (3) DK3587579T3 (enExample)
ES (3) ES2635388T3 (enExample)
PT (1) PT3587579T (enExample)
WO (1) WO2012006243A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014016870A2 (pt) 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
CA2978450A1 (en) * 2015-03-04 2016-09-09 The University Of Chicago Beta-catenin inhibitors in cancer immunotherapy
AU2017232496B2 (en) 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
AU2018244351A1 (en) * 2017-03-28 2019-10-17 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin expression to potentiate immunotherapy
US10407681B2 (en) * 2017-03-28 2019-09-10 The United States Of America, As Represented By The Secretary Of Agriculture Plant-mediated silencing of a fatty acid and retinoid binding protein in Pratylenchus penetrans
JP2021500026A (ja) * 2017-10-18 2021-01-07 ディセルナ ファーマシューティカルズ インコーポレイテッド βカテニン核酸阻害剤分子
WO2019100039A1 (en) * 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
MX2020009074A (es) * 2018-03-02 2020-10-08 Dicerna Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones asociadas a la deficiencia del conducto biliar.
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
AU2022316139A1 (en) * 2021-07-23 2024-01-18 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
DE69123979T2 (de) 1990-10-12 1997-04-30 Max Planck Gesellschaft Abgeänderte ribozyme
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ｉＲＮＡ複合体
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
JP5243789B2 (ja) * 2004-03-15 2013-07-24 シティ・オブ・ホープ 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2006031977A2 (en) * 2004-09-13 2006-03-23 The Regents Of The University Of California Inhibition of pancreatic cancer cell growth
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
CA2685444A1 (en) * 2007-05-01 2008-11-06 Jesper Worm Rna antagonist compounds for the modulation of beta-catenin
WO2008156661A2 (en) * 2007-06-15 2008-12-24 Beth Israel Deaconess Medical Center BACTERIAL MEDIATED TNF-α GENE SILENCING
TWI455944B (zh) * 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
JP2012005734A (ja) 2010-06-28 2012-01-12 Panasonic Corp 電気掃除機用吸込具及びそれを備えた電気掃除機
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)

Also Published As

Publication number Publication date
WO2012006243A2 (en) 2012-01-12
EP3037538B1 (en) 2019-05-01
US10612023B2 (en) 2020-04-07
EP2591105A2 (en) 2013-05-15
EP3037538A1 (en) 2016-06-29
AU2011276365B2 (en) 2017-05-11
PT3587579T (pt) 2021-05-24
CA2804214A1 (en) 2012-01-12
WO2012006243A3 (en) 2012-06-14
DK3587579T3 (da) 2021-04-26
US10072263B2 (en) 2018-09-11
EP3587579A1 (en) 2020-01-01
US20160186176A1 (en) 2016-06-30
DK3037538T3 (da) 2019-06-24
US9243244B2 (en) 2016-01-26
EP2591105A4 (en) 2014-09-10
JP2013534425A (ja) 2013-09-05
US20160053263A1 (en) 2016-02-25
AU2011276365A1 (en) 2013-01-10
US20130109740A1 (en) 2013-05-02
US20190002879A1 (en) 2019-01-03
EP3587579B1 (en) 2021-03-03
CA3146952A1 (en) 2012-01-12
DK2591105T3 (en) 2017-07-31
ES2873893T3 (es) 2021-11-04
ES2635388T3 (es) 2017-10-03
US9428752B2 (en) 2016-08-30
EP2591105B1 (en) 2017-05-31
HK1227054A1 (en) 2017-10-13
ES2734743T3 (es) 2019-12-11
US8815825B2 (en) 2014-08-26
EP3854874A1 (en) 2021-07-28
CA2804214C (en) 2022-04-12
US20140288292A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
JP5976643B2 (ja) 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物
JP6010458B2 (ja) 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
US8927515B2 (en) Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA
EP2756845A1 (en) Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
JP2015529467A (ja) 二本鎖ｒｎａによるｍｙｃの特異的阻害に関する方法および組成物
WO2010115202A2 (en) Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
WO2014093746A2 (en) Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
US10011834B2 (en) Methods and compositions for the specific inhibition of HIF-1α by double-stranded RNA
HK40059743A (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
HK1227054B (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160720

R150 Certificate of patent or registration of utility model

Ref document number: 5976643

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees